All Drug Discovery Processes articles – Page 31
-
ArticleABB’s robotics ecosystem: advancing lab efficiency in drug discovery
In this interview with Jose-Manuel Collados, learn how ABB's strategic partnerships and automation technology are improving lab efficiency, enhancing precision and ultimately speeding up the development of life-saving treatments.
-
NewsNew approach targets VHR enzyme for sepsis treatment
A new study reveals a promising approach to sepsis treatment by targeting the VHR enzyme using fragment-based drug discovery. This innovative method could lead to more effective therapies for sepsis and other immune-related conditions.
-
NewsDrug OLX-07010 shows promise in treating tau diseases
OLX-07010, a new drug from Oligomerix, shows potential in reducing tau protein tangles, a key factor in Alzheimer's and other tau-related diseases. Early studies suggest it could be a breakthrough in targeting tau aggregation and improving brain function.
-
NewsTract Bio identifies drug targets for oesophageal cancer
Tract Bio’s new research reveals key insights into the evolution of oesophageal adenocarcinoma (EAC) and identifies promising drug combinations for more effective treatment.
-
ArticleNew advances in hormone replacement therapy set to transform care
Hormone replacement therapy has long been used to treat low hormone levels, but existing delivery methods struggle with poor adherence and inconsistent hormone delivery. Lisa Stehno-Bittel of Likarda and Charles Virden of VitalTE discuss a novel approach using hormone-filled microbeads in hydrogels for steady, extended release after monthly self-injections.
-
ArticleWhy DNA Damage Response deserves renewed focus in cancer therapy
As cancer therapies evolve, a critical opportunity is emerging in the form of DNA Damage Response (DDR) research. With breakthroughs in genomics, drug delivery and AI, DDR pathways are set to overcome resistance and alter treatment strategies. Find out why now is the perfect moment to refocus on DDR, and ...
-
NewsNovel radioactive drug targets aggressive metastatic melanoma
Scientists in Japan have developed a new radioactive drug that emits alpha particles, showing promise for targeting metastatic melanoma - an aggressive skin cancer resistant to many conventional treatments.
-
ArticleThe evolution of AI in drug discovery: learning from history's mistakes (Part 2)
In this second part of a two-part series, we continue Sujeegar Jeevanandam’s exploration of the future of AI in drug discovery. We share his vision for transformative AI applications, such as simulating human pharmacokinetics and pharmacodynamics, and offer strategic recommendations for biotechs looking to adopt AI.
-
NewsNew research offers hope for high-grade glioma treatment
High-grade glioma, an aggressive brain cancer affecting both paediatric and adult patients, remains difficult to treat. A collaborative study from the University of Michigan, Dana-Farber Cancer Institute, and the Medical University of Vienna reveals a promising new treatment approach.
-
ReportBeyond the Lab: Artificial Intelligence
Download our latest report to discover how AI is transforming drug discovery, accelerating treatments and driving personalised care.
-
NewsNanoparticle therapy shows potential to prevent spread of pancreatic cancer to liver
Pancreatic cancer is notoriously hard to treat, especially when it spreads to the liver in advanced stages. Researchers at UCLA’s California NanoSystems Institute (CNSI) have developed an innovative nanoparticle technology to tackle this challenge.
-
NewsCeSPIACE: New peptide drug blocks COVID-19 variants
Scientists have developed CeSPIACE, a peptide drug that offers broad protection against COVID-19 variants, including Omicron XBB.1.5. Find out how it targets a stable part of the virus’s spike protein, making it resistant to mutations.
-
ArticleAbelacimab: the next frontier in safer anticoagulation therapy
Abelacimab represents a breakthrough in drug discovery, offering a novel approach to anticoagulation that could potentially prevent strokes with minimal bleeding risk. Learn how this innovative treatment could set new standards for both clinical practice and pharmaceutical research.
-
NewsFairJourney Biologics acquires Charles River’s South San Francisco facility
FairJourney Biologics S.A., a global leader in antibody discovery and optimisation, has announced its acquisition of Charles River Laboratories’ South San Francisco site.
-
NewsBeckman Coulter Life Sciences and Rarity Bioscience partner to advance oncology research
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, has partnered with Rarity Bioscience to introduce a groundbreaking approach to oncology research.
-
News
Scientists discover key to long COVID lung damage and potential treatment
Scientists at the University of Virginia (UVA) School of Medicine have uncovered a crucial mechanism behind the lingering effects of long COVID, revealing how severe COVID-19 infections impair immune cells’ ability to repair lung tissue.
-
ArticleThe future of mental health treatment: Zelquistinel's role
Learn about zelquistinel, an innovative NMDA receptor modulator that is transforming treatment possibilities through a novel approach to synaptic plasticity. This breakthrough drug offers new insights into early drug discovery and the future of neuropsychiatric treatment.
-
NewsFirst AI-designed drug, Rentosertib, officially named by USAN
Insilico Medicine’s AI-designed drug for idiopathic pulmonary fibrosis (IPF), Rentosertib, has been granted an official name by USAN. This is the first drug where both the target and compound were discovered using generative AI, marking a major milestone in AI-driven drug development.
-
ArticleThe evolution of AI in drug discovery: learning from history's mistakes (Part 1)
AI is transforming drug discovery, but its adoption mirrors past technological shifts in the industry. In this first part of a two-part series, we reveal Sujeegar Jeevanandam’s observations of the parallels between AI and the electronic lab notebook revolution, highlighting key challenges, lessons learned, and what the future holds for ...
-
ArticleNavigating the AI revolution: a roadmap for pharma’s future
AI-driven drug development, powered by advanced models and expanding data access, is becoming a reality. Learn why navigating regulatory hurdles and mastering biology’s inherent complexities are crucial to fully unlocking its potential.